Veeda Clinical Research IPO Details

Bookbuilding IPO | ₹[.] Cr | Listing at BSE, NSE |

Veeda Clinical Research IPO Logo

SEBI has approved the Initial Public Offer (IPO) of Veeda Clinical Research Ltd. on July 3, 2025. The company will proceed with next steps to launch the Initial Public Offer (IPO) subject to market conditions and other approvals. The SEBI approval is valid for 12 months.

Veeda Clinical Research Ltd. IPO is a Book Build Issue

The equity shares are proposed to be listed on NSE and BSE. Axis Capital Ltd. is the book running lead manager and MUFG Intime India Pvt.Ltd. is the registrar of the issue. Key details like IPO dates, IPO price bands and lot size are yet to be announced.
Refer to Veeda Clinical Research IPO DRHP for more details.

IPO Details

IPO Date[.]
Listing Date[.]
Face Value2 per share
Price Band
Lot Size
Sale TypeOFS only
Issue TypeBookbuilding IPO
Listing AtBSE, NSE

IPO DRHP Status

DescriptionDate
Filed with SEBI/ExchangeFri, Feb 7, 2025
SEBI/Exchange approval receivedThu, Jul 3, 2025

IPO Reservation

Investor Category Shares Offered
QIB Shares Offered Not More than 75% of the Net Offer
Retail Shares Offered Not more than 10% of the Net Offer
NII Shares OfferedNot more than 15% of the Net Offer

About Veeda Clinical Research Ltd.

Founded in April 2004, Veeda Clinical Research Limited is a full-service contract research organization (CRO) providing a comprehensive range of services in drug development, including non-clinical, pre-clinical, bioavailability, bioequivalence studies, and clinical trials for various drugs such as novel entities, generics, and biosimilars, as well as medical devices.

The company's services include the following.

  1. Early-phase and late phase clinical trials
  2. Healthy volunteer studies (“HVS”) which include bioavailability studies and bioequivalence studies
  3. Pre-clinical trials and non-clinical testing
  4. biopharma services include non-clinical analysis and clinical bioanalysis of large molecules.

As of September 30, 2024, the company completed 119 global regulatory inspections in HVS and Pre-Clinical services by authorities including the FDA, UK-MHRA, WHO, ANVISA, DCGI, EMA, and NPRA.

As of September 30, 2024, the company has over 436 active clients worldwide.

The company has successfully conducted studies for 417, 504, 498, and 580 clients during the six months ending September 30, 2024, and for the financial years 2024, 2023, and 2022, respectively.

As of September 2024, the company employs 914 people in various departments.

Competitive Strengths:

  • Established quality credentials with a strong focus on quality control management.
  • Successful integration of growth opportunities through acquisitions.
  • Global and diverse management team with deep scientific expertise.

 

Company Financials (Restated Consolidated)

Period Ended30 Sep 202431 Mar 202431 Mar 202331 Mar 2022
Assets1,891.862,040.21734.77677.54
Total Income315.87407.99420.21293.11
Profit After Tax-24.93-0.3642.4250.46
NET Worth1,192.511,190.96564.90503.21
Reserves and Surplus1,048.911,047.37446.58419.58
Total Borrowing405.49261.6948.5747.20
Amount in ₹ Crore

Key Performance Indicator (KPI)

KPIMar 31, 2023
Debt/Equity0.32
RoNW-0.02%
Pre IPOPost IPO
Promoter Holding33.83%
The promoter of the Company is Basil Private Limited.

IPO Registrar

MUFG Intime India Pvt.Ltd.

  • +91-22-4918 6270
  • Veedalifesciences.ipo@linkintime.co.in
  • Visit Website

Contact Details

Veeda Clinical Research Ltd. Address
Shivalik Plaza –A, 2nd Floor
Opposite Ahmedabad Management Association
Ambawadi
Ahmedabad, Gujarat, 380015
  • +91 79 6777 3000
  • investor.relation@veedalifesciences.com
  • Visit Website
Open an Instant Account with Zerodha

IPO FAQs

Veeda Clinical Research IPO is a main-board IPO of 0 equity shares of the face value of ₹2 aggregating up to ₹[.] Crores. The issue is priced at To be declared. The minimum order quantity is .

The Veeda Clinical Research IPO open and close dates are not available as of now.

MUFG Intime India Pvt.Ltd. is the registrar for the IPO. The shares are proposed to be listed on BSE, NSE.

Zerodha customers can apply online in Veeda Clinical Research IPO using UPI as a payment gateway. Zerodha customers can apply in Veeda Clinical Research IPO by login into Zerodha Console (back office) and submitting an IPO application form.

Steps to apply in Veeda Clinical Research IPO through Zerodha

  1. Visit the Zerodha website and login to Console.
  2. Go to Portfolio and click the IPOs link.
  3. Go to the 'Veeda Clinical Research IPO' row and click the 'Bid' button.
  4. Enter your UPI ID, Quantity, and Price.
  5. Submit IPO application form.
  6. Visit the UPI App (net banking or BHIM) to approve the mandate.

Visit Zerodha IPO Application Process Review for more detail.

The Veeda Clinical Research IPO dates are not announced. Please check back again after some time.

Veeda Clinical Research IPO lot size and the minimum order quantity is not available at this time. Please check again later.

You can apply in Veeda Clinical Research IPO online using either UPI or ASBA as a payment method. ASBA IPO application is available in the net banking of your bank account. UPI IPO Application is offered by brokers who don't offer banking services. Read more detail about applying IPO online through Zerodha, Upstox, 5Paisa, Nuvama, HDFC Bank, and SBI Bank.

The finalization of Basis of Allotment for Veeda Clinical Research IPO will be done on [.], and the allotted shares will be credited to your demat account by . Check the Veeda Clinical Research IPO allotment status.

The Veeda Clinical Research IPO listing date is not yet announced. The tentative date of listing is .

Compare: